A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

PubMed Daily Triage — 2026-06-24

Window: 2026-06-23 09:05 UTC → 2026-06-24 09:00 UTC
Total candidates reviewed: ~127 across 10 topics
Accepted: 23 (13 HIGH · 10 MEDIUM)
Alert sent: 13 HIGH-priority articles → Telegram

🔴 HIGH PRIORITY (Score ≥ 8)

T3 · Liquid Biopsy / ctDNA

[PMID 42332784] Akbarinejad S et al. · Genome Med · 2026-06-23
DEEPctMUT: Tumor-naïve ctDNA detection with deep learning-enhanced error suppression
DOI: 10.1186/s13073-026-01694-y
→ Achieves 0.03% VAF sensitivity (tumor-naïve). 100% sensitivity in pre-surgical CRC vs 50% for Roche Avenio. Combines UMIs + ML error suppression + PBMC germline filtering. Open-source Nextflow pipeline from TRON/BioNTech.
🏷️ Score 9/10 · Methods · Abstract confirmed

[PMID 42336205] Horndalsveen H et al. · J Thorac Oncol · 2026-06-23
ctDNA-based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab
DOI: 10.1016/j.jtho.2026.103992
→ Prospective multicenter (84 pts, 659 samples). Detectable ctDNA during durvalumab = HR 2.95 for progression. Serial MRD-positive status identifies patients warranting treatment escalation. Direct clinical application in PACIFIC-like regimen.
🏷️ Score 9/10 · Prospective · Abstract confirmed

T5 / T6 · Precision Oncology & Novel Therapeutics

[PMID 42336869] Wang HH et al. · Nat Commun · 2026-06-23
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial
DOI: 10.1038/s41467-026-74711-8
→ Johns Hopkins Phase I: KRAS mutant neoantigen peptide vaccine + nivolumab + ipilimumab (dual checkpoint blockade) in mCRC. Nature Comms publication from Jaffee lab signals promising safety/efficacy signals in a historically difficult target.
🏷️ Score 9/10 · Phase I RCT · Title confirmed

[PMID 42337235] Kinsella Z et al. · Nat Commun · 2026-06-23
Spatial analyses implicate high stromal CD8+ TILs as negative predictive marker for chemotherapy in ER+ breast cancer
DOI: 10.1038/s41467-026-73432-2
→ Spatial TIL quantification identifies immunologically active ER+ tumors where chemotherapy confers less benefit — may allow sparing of cytotoxic therapy in specific patients. Nat Comms with clinical translation potential.
🏷️ Score 8/10 · Spatial/Retrospective · Title confirmed

[PMID 42337043] Yuan J et al. · Br J Cancer · 2026-06-23
Infigratinib Phase 2 in refractory FGFR2-amplified gastric/GEJ adenocarcinoma
DOI: 10.1038/s41416-026-03511-0
→ Single-arm multicenter Phase 2: FGFR inhibitor in biomarker-selected upper GI cancer. Addresses actionable alteration in a historically chemo-resistant population. Directly extends precision oncology to gastroesophageal junction.
🏷️ Score 8/10 · Phase 2 · Title confirmed

[PMID 42335902] Grande E et al. · Cell Rep Med · 2026-06-23
Spatial architecture explains bulk biomarker failure in neoadjuvant immunotherapy for bladder cancer: DUTRENEO study
DOI: 10.1016/j.xcrm.2026.102878
→ DUTRENEO clinical trial correlative: spatial tumor architecture outperforms bulk genomic biomarkers for immunotherapy patient selection. Cell Rep Med trial-linked publication — paradigm shift toward spatial pathology over bulk assays.
🏷️ Score 8/10 · Clinical Trial Correlative · Title confirmed

[PMID 42336655] Roulleaux-Dugage M et al. · J Immunother Cancer · 2026-06-23
VEGF-A blockade rescues chemoimmunotherapy resistance in NSCLC with liver metastases
DOI: 10.1136/jitc-2026-014991
→ IMpower130/150 post-hoc (N=1,713; 236 LM+): bevacizumab + CT+IT → OS HR 0.52, PFS HR 0.49 specifically in liver met+ patients. scRNAseq reveals VEGF-A-driven immunosuppressive TME in liver. First comparative analysis in this subgroup.
🏷️ Score 8/10 · Phase III Post-Hoc · Abstract confirmed

T4 · AI in Clinical Diagnostics

[PMID 42336244] Deman F et al. · Lab Invest · 2026-06-23
AI-assisted HER2 IHC scoring in breast cancer: diagnostic agreement and discordance analysis
DOI: 10.1016/j.labinv.2026.106150
→ 853 whole-slide images, 581 patients. CE-IVD-approved AI evaluated against expert pathologists for HER2 IHC scoring, including HER2-low/ultralow spectrum now critical for trastuzumab deruxtecan (T-DXd) eligibility. Multi-center expert comparison.
🏷️ Score 8/10 · Diagnostic Validation · Abstract confirmed

[PMID 42335604] · Med Image Anal · 2026-06-23
MICLEAR: AI-assisted intraoperative pancreatic cancer resection margin assessment
→ Real-time AI guidance for R0/R1 margin determination during pancreatic surgery. Addresses a critical unmet need — positive margins are a major driver of poor outcomes in pancreatic cancer. Med Image Anal flagship surgical AI paper.
🏷️ Score 8/10 · AI Validation · Title only

T7 · Cardiometabolic / GLP-1 / SGLT2

[PMID 42335894] · Cell Metab · 2026-06-23
Methionine-supplemented longevity diet increases GH, GLP-1, and FGF21; reduces frailty
DOI: 10.1016/j.cmet.2026.05.015
→ Cell Metab (IF ~30): dietary methionine supplementation elevates GLP-1, growth hormone, and FGF21 while reducing frailty markers. Directly connects dietary intervention to established metabolic longevity pathways.
🏷️ Score 8/10 · Experimental · Partial abstract

[PMID 42335597] · JACC Adv · 2026-06-23
SGLT2 inhibitors and outcomes after TAVI: systematic review and meta-analysis
→ First meta-analysis examining SGLT2i use after transcatheter aortic valve implantation. As TAVI volumes grow and SGLT2i indications expand, this addresses a clinically urgent pharmacotherapy question in older, high-comorbidity patients.
🏷️ Score 8/10 · Meta-Analysis · Title confirmed

T8 · Aging / Longevity

[PMID 42337381] Xian S et al. · NPJ Digit Med · 2026-06-23
100,272 EHR patients: unsupervised ML identifies comorbidity clusters linked to premature aging
DOI: 10.1038/s41746-026-02913-x
→ Largest-scale unsupervised EHR phenotyping study of biological aging. Identifies high-risk patient groups through comorbidity patterns — bridges AI diagnostics and population-level aging biology with direct clinical translation.
🏷️ Score 8/10 · EHR/ML Cohort · Title confirmed

T8 / T9 · Aging & Rare Disease

[PMID 42334294] Schratz KE, Armanios M · NEJM Evid · 2026-06-23
Disorders of Telomere Length (review)
DOI: 10.1056/EVIDra2600012
→ Authoritative NEJM Evidence review from Armanios lab. Short telomeres → BMF/IPF/immunodeficiency. Ultra-long telomeres → lympho/myeloproliferative disease, early clonal hematopoiesis. Clinical guidance for a spectrum of rare and common diseases.
🏷️ Score 8/10 · Review · Abstract confirmed

🟡 MEDIUM PRIORITY (Score 6–7)

PMID	Title (abbreviated)	Journal	Topics	Score
42335901	Radiopharmaceutical enhances CAR-T in neuroblastoma	Cell Rep Med	T6/T9	7
42333941	Aging clock from immune repertoire; COVID-19 accelerates aging	Aging Cell	T8	7
42336688	Phase I copanlisib + venetoclax in R/R DLBCL	Clin Lymphoma Myeloma Leuk	T1	7
42335650	Long-term remission in IDH-mutated AML with IDH inhibitors	Leuk Res	T1	7
42335205	Loss of miR-146a-5p drives ibrutinib resistance in MCL	Blood Adv	T1	7
42334419	cf-MMSP methylated cfDNA assay for breast cancer detection	Cancer Epidemiol Biomarkers Prev	T3	7
42335576	Colonoscope mucus KRAS detection in precancerous CRC lesions	Transl Oncol	T3	7
42335861	LLMs show greater diagnostic anchoring than physicians	Int J Med Inform	T4	7
42335260	Real-world semaglutide vs dulaglutide weight loss in T2DM	Am J Manag Care	T7	7
42335902	(also in HIGH — see above)	Cell Rep Med	T5/T6	8

📊 Run Statistics

Topic	Hits	Candidates	Accepted	HIGH	MEDIUM
T1: Hematologic malignancies	62	20	6	0	6
T2: CBC/ML	1	1	0	0	0
T3: Liquid biopsy/ctDNA	10	10	4	2	2
T4: AI diagnostics	37	20	4	2	2
T5: Precision oncology	39	20	5	3	2
T6: Novel therapeutics	56	20	5	2	3
T7: Cardiometabolic	38	20	4	2	2
T8: Aging/longevity	22	20	4	2	2
T9: Rare diseases	5	5	1	1	0
T_sentinel	299	10	2	1	1
TOTAL	~569	~127	23	13	10

⚙️ Query Notes / Improvements for Next Run

T2 (CBC/ML): Only 1 hit — query too restrictive. Add morphology[tiab] OR cell differential[tiab] OR automated hematology[tiab].
T8 (Aging): humans[MeSH] filter excluded some relevant papers. Consider adding epigenetic clock[tiab] OR biological age[tiab].
T_sentinel: 299 hits is too broad to triage. Add high-impact journal ISSN filter or clinical trial[pt] restriction.
T5: Current expansion working well — KRAS vaccine and infigratinib trial both captured.

Generated: 2026-06-24 09:05 UTC | Run by friday/pubmed-triage v1.3 | 13 HIGH alerts sent to Telegram

Daily digest